Characterization of the heparin-binding properties of IL-6

Journal of Immunology

Volumn 165, Issue 10, 2000, Pages 5671-5679

  Mummery, R S ^a   Rider, C C ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN 4 SULFATE; CHONDROITIN 6 SULFATE; DERMATAN SULFATE; EPITOPE; GLYCOPROTEIN; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; INTERLEUKIN 6; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 6;

ANTIBODY SPECIFICITY; ARTICLE; BINDING COMPETITION; CYTOKINE RELEASE; DIMERIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

EID: 0034669968     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.10.5671     Document Type: Article

References (52)

1. Interleukin-6 in biology and medicine
2. New insights into the cellular, biochemical and molecular basis of postmenopausal and senile osteoporosis: Roles of IL-6 and gp130
3. Up-regulation of leukemia inhibition factor and interleukin-6 in transected sciatic nerve and muscle following denervation
4. Impaired immune and acute-phase responses in interleukin-6-deficient mice
5. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses
6. Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice
7. Accelerated nerve regeneration in mice by up-regulated expression of interleukin (IL) 6 and IL-6 receptor after trauma
8. Interleukin 6 is required for the development of collagen-induced arthritis
9. Interleukin 6 plays a key role in the development of antigen-induced arthritis
10. Inactivation of the IL-6 gene prevents development of multicentric Castleman's disease in C/EBPβ-deficient mice
11. Therapeutic strategies for the inhibition of interleukin-6 mediated multiple myeloma cell growth
12. Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies
13. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6
14. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma
15. 1.9Å crystal structure of interleukin 6: Implications for a novel mode of receptor dimerization and signaling
16. Solution structure of recombinant human interleukin-6
17. Molecular cloning and expression of an IL-6 signal transducer, gp130
18. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130
19. High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6-receptor, and gp130
20. The function of the soluble interleukin 6 (IL-6) receptor in vivo: Sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6
21. The extended family of proteoglycans: Social residents of the pericellular zone
22. Cell surface heparan sulfate proteoglycans
23. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation
24. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor
25. Heparin decreases the blood clearance of interferon-γ and increases its activity by limiting the processing of its carboxyl-terminal sequence
26. Characterization of human recombinant interleukin 2 binding to heparin and heparan sulfate
27. Further characterization of the binding of human recombinant interleukin 2 to heparin and identification of putative binding sites
28. IL-12 is a heparin binding cytokine
29. Anti-HIV-1 activity of chemically modified heparins: Correlation between binding to the V3 loop of gp120 and inhibition of cellular HIV-1 infection in vitro
30. Structure-function analysis of human IL-6: Epitope mapping of the neutralizing antibodies with amino- and carboxyl-terminal deletion mutants
31. Monoclonal antibodies to the soluble human IL-6 receptor: Affinity purification, ELISA and inhibition of ligand binding
32. Mediation of interleukin-11-dependent biological responses by a soluble form of the interleukin-11 receptor
33. Heparan sulphate bound growth factors: A mechanism for stromal cell mediated haemopoiesis
34. GM-CSF and IL-3 activities in schistosomal liver granulomas are controlled by stroma-associated heparan sulfate proteoglycans
35. Human interleukin 4 is a glycosaminoglycan-binding protein
36. Interleukin-5 binds to heparin/heparan sulfate: A model for an interaction with extracellular matrix
37. Interaction of interleukin 7 (IL-7) with glycosaminoglycans and its biological relevance
38. Binding of heparan sulfate or heparin enhances neutrophil responses to interleukin 8
39. A revised structure for fucoidan may explain some of its biological activities
40. Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate
41. Analysis of the mechanism of action of anti-human interleukin-6 and anti-human interleukin-6 receptor neutralizing monoclonal antibodies
42. Cloning and expression of the human interleukin (BSF-2/IFNβ2) receptor
43. Cell-surface heparan sulfate facilitates human immunodeficiency virus type 1 entry into some cell lines but not primary lymphocytes
44. Generation of interleukin-6 receptor antagonists by molecular-modeling guided mutagenesis of residues important for gp130 activation
45. Analysis of the mechanism of the human interleukin-6/human interleukin-6 receptor binding interface at the amino acid level: Proposed mechanism of interaction
46. Glycosaminoglycan-protein interactions: Definition of consensus sites in glycosaminoglycan binding proteins
47. Glycosaminoglycan-protein interactions: A question of specificity
48. Interleukin-6: Structure-function relationships
49. Proteoglycans: Master regulators of molecular encounter?
50. Distinct classes of chaperoned IL-6 in human blood: Differential immunological and biological availability
51. Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo
52. Suramin inhibits the stimulation of acute phase plasma protein genes by IL-6-type cytokines in rat hepatoma cells